Supernus Pharmaceuticals Completes Merger with Indivior Pharmaceuticals

Supernus Pharmaceuticals completed its merger with Indivior Pharmaceuticals on November 2, 2026, forming a combined company named Supernus, Inc. The company is scheduled to begin trading on the Nasdaq Global Market under ticker SUPN on November 3. The combined business has an 11-product portfolio focused on central nervous system conditions, including opioid use disorder, psychiatry and neurology; management said the merger increases its financial scale and cash flow and supports pipeline development and future growth.